NCT06836284View on ClinicalTrials.gov

The Evira Study: Additional Support During Anti-Obesity Treatment

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

August 29, 2026

Study Completion Date

October 31, 2026

Conditions
Childhood ObesityTreatment Adherence
Interventions
DEVICE

Digi-physical treatment tool, Evira

A digi-physical treatment tool named Evira will be used to provide behavioral treatment.

DRUG

Anti-obesity medication with liraglutide or semaglutide

Anti-obesity medication with liraglutide or semaglutide according to the clinic's standard procedure

Trial Locations (1)

Unknown

HKH Crown Princess Victoria's Childrens and youth Hospital Linköping, Linköping

Sponsors

Collaborators (1)

Evira AB
All Listed Sponsors
collaborator

Evira AB

INDUSTRY

lead

Karolinska Institutet

OTHER

NCT06836284 - The Evira Study: Additional Support During Anti-Obesity Treatment | Biotech Hunter | Biotech Hunter